The North America High Intensity Focused Ultrasound Market would witness market growth of 6.6% CAGR during the forecast period (2024-2031).
The US market dominated the North America High Intensity Focused Ultrasound Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $489.6 million by 2031. The Canada market is exhibiting a CAGR of 8.9% during 2024-2031. Additionally, the Mexico market would experience a CAGR of 8% during 2024-2031.
High intensity focused ultrasound (HIFU) is a non-invasive medical procedure that uses focused ultrasound waves to generate high temperatures in targeted tissues. This localized heat destroys or disrupts abnormal tissue. HIFU has found applications in several medical disciplines, each leveraging the technology’s unique ability to deliver targeted treatment without requiring surgical incisions. In oncology, HIFU treats solid tumours, including prostate, liver, and pancreatic cancers. By precisely focusing ultrasound waves on cancerous tissues, HIFU induces thermal ablation, which destroys tumour cells while sparing surrounding healthy tissues. This application is particularly valuable for patients who are not suitable candidates for traditional surgery or radiation therapy.
One of the most established applications of HIFU is in the treatment of prostate cancer. HIFU offers a minimally invasive alternative to traditional prostatectomy and radiation therapy, providing targeted treatment with reduced side effects and faster recovery times. Additionally, HIFU is used to manage benign prostatic hyperplasia (BPH) and other urological conditions.
The growth in cancer incidence may lead to the expansion of oncology services across Mexico. Hospitals and clinics could invest in HIFU technology as a non-invasive treatment option, particularly in urban areas where healthcare infrastructure is rapidly developing. According to the All. Can, cancer is the third leading cause of death in Mexico. Over 195,000 new cases were registered in 2020. Breast (29.929), prostate (26.742), thyroid (11,227), colon (11,191), and cervical cancer (9,439) were among those with the highest prevalence. As cancer cases increase, the Mexican government may prioritize funding and initiatives to combat the disease. This could include investments in advanced treatment technologies like HIFU, integrating them into public healthcare facilities to improve cancer care outcomes. In conclusion, increasing incidence of cancer in the region is driving the growth of the market.
The US market dominated the North America High Intensity Focused Ultrasound Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $489.6 million by 2031. The Canada market is exhibiting a CAGR of 8.9% during 2024-2031. Additionally, the Mexico market would experience a CAGR of 8% during 2024-2031.
High intensity focused ultrasound (HIFU) is a non-invasive medical procedure that uses focused ultrasound waves to generate high temperatures in targeted tissues. This localized heat destroys or disrupts abnormal tissue. HIFU has found applications in several medical disciplines, each leveraging the technology’s unique ability to deliver targeted treatment without requiring surgical incisions. In oncology, HIFU treats solid tumours, including prostate, liver, and pancreatic cancers. By precisely focusing ultrasound waves on cancerous tissues, HIFU induces thermal ablation, which destroys tumour cells while sparing surrounding healthy tissues. This application is particularly valuable for patients who are not suitable candidates for traditional surgery or radiation therapy.
One of the most established applications of HIFU is in the treatment of prostate cancer. HIFU offers a minimally invasive alternative to traditional prostatectomy and radiation therapy, providing targeted treatment with reduced side effects and faster recovery times. Additionally, HIFU is used to manage benign prostatic hyperplasia (BPH) and other urological conditions.
The growth in cancer incidence may lead to the expansion of oncology services across Mexico. Hospitals and clinics could invest in HIFU technology as a non-invasive treatment option, particularly in urban areas where healthcare infrastructure is rapidly developing. According to the All. Can, cancer is the third leading cause of death in Mexico. Over 195,000 new cases were registered in 2020. Breast (29.929), prostate (26.742), thyroid (11,227), colon (11,191), and cervical cancer (9,439) were among those with the highest prevalence. As cancer cases increase, the Mexican government may prioritize funding and initiatives to combat the disease. This could include investments in advanced treatment technologies like HIFU, integrating them into public healthcare facilities to improve cancer care outcomes. In conclusion, increasing incidence of cancer in the region is driving the growth of the market.
List of Key Companies Profiled
- EDAP TMS S.A
- Sonablate Corp.
- Verasonics, Inc.
- ALPINION MEDICAL SYSTEMS Co., Ltd.
- Theraclion
- Lynton Lasers Ltd
- ULTRAISER
- PROFOUND MEDICAL CORP.
Market Report Segmentation
By End Use
- Hospital
- Imaging Centers
- Others
By Application
- Dermatology
- Uterine Fibroids
- Prostate Cancer
- Essential Tremor
- Breast Cancer
- Glaucoma
- Backpain, Facetogenic
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America High Intensity Focused Ultrasound Market by End Use
Chapter 5. North America High Intensity Focused Ultrasound Market by Application
Chapter 6. North America High Intensity Focused Ultrasound Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- EDAP TMS S.A
- Sonablate Corp.
- Verasonics, Inc.
- ALPINION MEDICAL SYSTEMS Co., Ltd.
- Theraclion
- Lynton Lasers Ltd
- ULTRAISER
- PROFOUND MEDICAL CORP.
Methodology
LOADING...
